Biohaven Ltd. (BHVN)
NYSE
Real-time Data
01:30 PM
Day's Range
13.5352 wk Range
7.48Overview - BHVN - Biohaven Ltd.
Key Statistics
Valuation
Enterprise Value
2.12B
P/E (Trailing)
‪-2.01‬
P/E (Forward)
‪-6.97‬
PEG Ratio
‪0.03‬
Price / Book
‪170.98‬
EV / EBITDA
‪-4.07‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-71.97%‬
Return on Equity
‪-799.46%‬
Ownership
Shares Outstanding
150.50M
Float
116.57M
Short % of Shares Outstanding
‪15.41%‬
Held by Insiders
‪11.20%‬
Held by Institutions
‪96.64%‬
Price stats
Beta
‪3.16‬
50-Day Avg
‪14.45‬
200-Day Avg
‪11.38‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
17 analysts
Average price target
‪$ 23.07‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BHVN - Biohaven Ltd.
Peers - BHVN - Biohaven Ltd.
Peer Comparison
Compared with companies in Biotechnology listed on NYSE.
- BHVNNYSEBiohaven Ltd.2.09BMarket Cap-7.87%52-week change-2.02P/E (Trailing)‪0.00%‬Profit Margin
- BIONYSEBio-Rad Laboratories Inc.10.16BMarket Cap+21.75%52-week change46.50P/E (Trailing)‪8.58%‬Profit Margin
- BSTNYSEBlackRock Science and Technology Trust1.72BMarket Cap+20.82%52-week change6.90P/E (Trailing)‪0.00%‬Profit Margin
- ANRONYSEAlto Neuroscience Inc.1.34BMarket Cap+88.51%52-week change-15.62P/E (Trailing)‪0.00%‬Profit Margin
- BCXNYSEBlackRock Resources & Commodities Strategy Trust1.00BMarket Cap+25.06%52-week change4.60P/E (Trailing)‪0.00%‬Profit Margin
- ATTONYSEAttovia Therapeutics Inc.895.00MMarket Cap-5.29%52-week change-8.78P/E (Trailing)‪0.00%‬Profit Margin
- ARMPNYSEArmata Pharmaceuticals Inc.189.62MMarket Cap+49.02%52-week change-1.05P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - BHVN - Biohaven Ltd.
About
Biohaven Ltd. is a clinical-stage biopharmaceutical company that focuses on creating novel therapies for neurological and neuropsychiatric diseases. Its primary function is to develop innovative drugs that address unmet medical needs, particularly in critical areas such as migraine relief and neurodegenerative…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
